Drug firm Ind Swift Laboratories today said its shareholders have approved raising funds up to Rs 500 crore through issue of securities.
The members have approved to raise funds up to Rs 500 crore through issue of Global Depositary Receipts (GDRs), Foreign Currency Convertible Bonds (FCCBs) and Convertible Bonds, Ind Swift Laboratories said in a filing to the Bombay Stock Exchange (BSE).
However, the company did not provide a time line for raising the funds.
"The members have also approved declaration of dividend of Re 1 per share of face value of Rs 10 each for the financial year 2010-11," it said.
The Chandigarh-based firm is into manufacturing of active pharmaceutical ingredients.
Shares of Ind Swift Laboratories today closed at Rs 83.75 on the BSE, up 0.72% from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app